We observed an upregulation of 50 hallmark pathways related to immune reactions, cancer progression, and immunotherapy in AML patients [31], such as hypoxia, MYC target v1, oxidative phosphorylation, P53 pathway, and heme metabolism (Fig. 3e) [34, 35]. Here, MYC is linked to acute myeloid leukemia.